Clinical Trial

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-04
notable Primary completion moved earlier: 2026-08-30 -> 2026-06-30 2026-08-04
minor Completion moved earlier: 2026-08-30 -> 2026-06-30 2026-08-04
Trial Details
NCT Number NCT06139419
Lead Sponsor Sun Yat-sen University
Conditions Non-small Cell Lung Cancer
Enrollment 114 participants
Start Date 2023-07-25
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-03